RxDoctor Payments DataLook up a doctor →

Michael Hassman, DO

Adult Medicine · Berlin, NJNPI 1922002765

Payments from drug & device makers

$22,609,229in general payments, 2019–2025

Across 1,658 payments — averaging $13,636 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5.7M
  • E.r. Squibb & Sons, L.L.C.$3.5M
  • Sunovion Pharmaceuticals Inc.$1.4M
  • Eli Lilly$1.4M
  • Modernatx, Inc.$1.2M
  • Janssen Research & Development, LLC$1.1M
  • plus $8.3M from 54 others
$289,334in research payments, 2019–2025

Across 20 payments — averaging $14,467 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orexo US, Inc.$261K
  • Nielsen Biosciences, Inc.$14K
  • Eli Lilly$9K
  • Shire North American Group Inc$5K
  • Takeda Pharmaceuticals U.S.A., Inc.$378
  • Purdue Pharma L.p.$375

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca38$5,680,850
E.r. Squibb & Sons, L.L.C.12$3,539,562
Sunovion Pharmaceuticals Inc.25$1,445,428
Eli Lilly16$1,367,598
Modernatx, Inc.37$1,183,025
Janssen Research & Development, LLC48$1,111,756
AbbVie(2 entities)148$1,043,230
Pfizer195$822,551
Astrazeneca UK Limited12$810,455
GSK60$731,586
Sanofi Pasteur Inc.10$613,281
Indivior Inc.125$555,807
Tris Pharma Inc23$431,594
Viiv Healthcare Company34$395,075
Genentech, Inc.17$369,156
Roche Diagnostics Operations, Inc.21$365,241
Novartis21$359,762
Vertex5$285,649
Otsuka Pharmaceutical Development & Commercialization, Inc.10$265,794
Vanda Pharmaceuticals Inc.30$239,926
Regeneron37$209,879
Incyte Corporation26$202,024
Merck13$152,149
Alnylam Pharmaceuticals Inc.34$134,437
Applied Therapeutics, Inc.32$120,759
Sanofi US Services Inc.14$61,058
Pacira Therapeutics, Inc.2$22,750
CSL Behring12$14,218
Chiesi USA, Inc.4$13,264
Abbott1$9,250
Acadia Pharmaceuticals Inc2$8,750
Pear Therapeutics (US), Inc.1$7,500
Noven Pharmaceuticals, Inc.8$6,788
Lexicon Pharmaceuticals, Inc.3$5,944
Biohaven Pharmaceuticals, Inc.8$4,644
Hexal AG22$2,994
Paratek Pharmaceuticals, Inc.2$2,731
Teva Pharmaceuticals USA, Inc.6$2,051
Amgen(2 entities)177$1,845
AMAG Pharmaceuticals, Inc.1$1,404
Akebia Therapeutics Inc3$982
Alkermes, Inc.32$507
Kowa Pharmaceuticals America, Inc.34$453
Hikma Pharmaceuticals USA2$396
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC26$374
Otsuka America Pharmaceutical, Inc.23$368
Amarin Pharma, Inc.30$343
Endo Pharmaceuticals Inc.1$341
Exact Sciences19$330
Johnson & Johnson(2 entities)23$324
Novo Nordisk28$299
Lilly USA, LLC20$284
Braeburn Inc.9$265
Madrigal Pharmaceuticals9$254
Topcon Healthcare Solutions, Inc.2$227
Lundbeck LLC11$186
Sumitomo Pharma America, Inc.1$155
Biohaven Pharmaceutical Holding Company Ltd.15$151
Takeda Pharmaceuticals U.S.A., Inc.4$95
Axsome Therapeutics, Inc.6$90

How this compares

$22,609,229 in reported general payments places this provider in the 95th percentile of 48 adult medicine providers in New Jersey.

See all adult medicine providers in New Jersey →

Medicare billing

Part B allowed, 2024
$259,478
Medicare patients
530
Services billed
5,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other adult medicine in Berlin

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →